Harbert institute for innovation and entrepreneurship
UAB researchers have secured a patent for a novel lens design that could slow myopia progression in children, translating decades of vision science research into potential clinical therapies.
PreciPS identifies frontline frustrations before providing operational solutions in patient care.
Recent innovations include a noninvasive external urine collection device, a system designed to simplify how clinicians manage fluid balance in critically ill patients, an ergonomic assist device for ureteroscopy and new ways to prevent kidney stones.
UAB researchers are developing a new at-home cervical cancer screening device aimed at increasing access to screening and improving early detection.
UAB scientists discovered an oral drug stopped weight rebound after discontinuation or cessation of GLP‑1 treatment in preclinical studies, opening the door to a new approach for maintaining weight loss.
Functional neurological disorder, an often-misunderstood condition, affects brain-body communication, causing involuntary seizures, movement difficulties and speech problems.
UAB’s first nonprofit startup, Dream a Little Dream, is improving global cystic fibrosis care by empowering medical teams with cost-effective tools and training.
The Blazer Bridge Fund encourages discovery among the UAB community by providing financial support to innovative ideas and inventions.
Michael Niederweis, Ph.D., and Cynthia Owsley, Ph.D., who collectively hold 23 patents, have been recognized for approaches to DNA sequencing and detection of impaired dark adaptation, respectively.
Rothenberg’s innovative, FDA-approved technology will improve cardiac health through enhanced treatment and prevention.
Yager’s journey as a Blazer is filled with institutional, national and international recognition; her most recent milestone is her unique patented catalytic reactor for NASA missions that has multiple applications in various other industries.
Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery.
This live biotherapeutic product, tested in mouse models, shows promise in addressing common pathways of lung disease progression.
The novel drug TIX100 functions differently from any approved diabetes drug to promote proper islet cell function.
Fobian developed Retraining and Control Therapy, or ReACT, to help patients with functional neurological disorder, or FND, which affects an estimated 300,000 Americans.
Ninety-two percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months. Glioblastoma multiforme is the most aggressive type of cancer originating in the brain.
Awards and honors continue for the PRCA/PRSSA at UAB chapter, where students put their classroom learning into real-world practice, preparing them for careers and vaulting them into the professional world.
National conference hosted by UAB attracts entrepreneur educators from around the nation to Birmingham.
UAB received the IEP Innovation award, recognizing exemplary initiatives spurring innovation, entrepreneurship and technology-based economic development.
This record-breaking funding marks a 73 percent growth in research awards over nine years.